Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.62 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908199 | 0.87 | BAZ2B (0.57) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL16364739 | 0.87 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL3113139 | 0.85 | BAZ2B (0.54) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL5546234 | 0.84 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL9192084 | 0.84 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL7377017 | 0.84 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL9285452 | 0.83 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL14791060 | 0.83 | GABRA1 (0.50) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL9151583 | 0.82 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1GAAKMT2A | |
| SCHEMBL9147935 | 0.82 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-9150563-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2683719-B1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | LILLY CO ELI (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2683719-B1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | LILLY CO ELI (US) | 2015-03-18 | — | — | EP | disclosed |
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-03 | — | — | US | disclosed |
| CN-103848835-A | Dipeptidyl peptidase-IV inhibitor, application thereof, intermediate body thereof and preparation method of intermediate body thereof | SHANGHAI SUN SAIL PHARMACEUTICAL SCIENCE & TECHNOLOGY CO LTD | 2014-06-11 | — | — | CN | disclosed |
| US-8648103-B2 | Nitrogen-containing aromatic heterocyclyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-11 | — | — | US | disclosed |
| EP-2683719-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | Eli Lilly and Company (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314092-B2 | Substituted [(5H-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HT2A antagonists | ELI LILLY AND COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| WO-2012109011-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012109011-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120108639-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202797-A1 | SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | HTR2A, HTR1A, HTR2C | BAZ2B 1984/4885BAZ2A 1161/4885ALDH1A1 818/4885 |
| US-20140187592-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | NPR1, NPR3, NPC1 | BAZ2B 1850/4885BAZ2A 2513/4885ALDH1A1 1307/4885 |
| US-20120108639-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND | NPR1, NPR3, NPPA | BAZ2B 2503/4885BAZ2A 3011/4885ALDH1A1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.